Sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation: does mTOR inhibitors association augment toxicity?

Eur J Gastroenterol Hepatol. 2014 May;26(5):577-8. doi: 10.1097/MEG.0000000000000073.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antineoplastic Agents / adverse effects*
  • Carcinoma, Hepatocellular / enzymology
  • Carcinoma, Hepatocellular / pathology
  • Carcinoma, Hepatocellular / therapy*
  • Drug Interactions
  • Everolimus
  • Humans
  • Immunosuppressive Agents / adverse effects*
  • Liver Neoplasms / enzymology
  • Liver Neoplasms / pathology
  • Liver Neoplasms / therapy*
  • Liver Transplantation*
  • Male
  • Middle Aged
  • Molecular Targeted Therapy
  • Neoplasm Recurrence, Local*
  • Niacinamide / adverse effects
  • Niacinamide / analogs & derivatives*
  • Phenylurea Compounds / adverse effects*
  • Protein Kinase Inhibitors / adverse effects*
  • Sirolimus / adverse effects
  • Sirolimus / analogs & derivatives*
  • Sorafenib
  • TOR Serine-Threonine Kinases / antagonists & inhibitors*
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Immunosuppressive Agents
  • Phenylurea Compounds
  • Protein Kinase Inhibitors
  • Niacinamide
  • Everolimus
  • Sorafenib
  • MTOR protein, human
  • TOR Serine-Threonine Kinases
  • Sirolimus